Sweden-based AlzeCure Pharma AB (STO: ALZCUR) out-licensed global rights to its NeuroRestore platform and lead ACD856 drug candidate to Denmark-based QuantumCell ApS in a deal worth more than USD 2.2 billion in milestones, just three weeks after AlzeCure signed a separate Alzheimer's licensing agreement with Eli Lilly.
ACD856 is a small-molecule positive allosteric modulator of both TrkA and TrkB neurotrophin receptors — a first-in-class mechanism — that has completed Phase Ib development and is being prepared for Phase II studies in Alzheimer's patients. The transaction gives QuantumCell, a company formed in December 2025 and backed by Lundbeckfonden and Novo Holdings, its first asset and positions it as the development vehicle for one of the more mechanistically novel small molecules in the Alzheimer's pipeline.
Under the terms, AlzeCure receives a total upfront payment of USD 12 million, of which USD 5 million constitutes a direct equity investment in AlzeCure at a 30% premium to the 10-day average share price of SEK 3.78. The remaining USD 7 million represents a cash license fee. The agreement also includes development and commercial milestone payments and tiered royalties ranging from single-digit to low double-digit percentages on net sales. The total deal value excluding royalties exceeds USD 2.2 billion. The transaction is subject to closing conditions including approval by Swedish and Danish authorities under foreign direct investment regulations.
Deal context
ACD856 acts as a Trk positive allosteric modulator (Trk-PAM), enhancing the brain's endogenous response to nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) rather than directly activating or blocking the receptors. Because the molecule amplifies existing neurotrophin signaling rather than substituting for it, its activity is ligand-dependent — a design intended to preserve physiological context and avoid the overstimulation risks associated with direct agonism. Preclinical studies reported by AlzeCure have indicated neuroprotective, anti-inflammatory, and disease-modifying effects; earlier clinical data showed ACD856 crosses the blood-brain barrier at relevant concentrations and activates neural pathways important for cognition.
AlzeCure reported positive Phase Ib results for ACD856 in June 2026, with the compound demonstrating acceptable safety and tolerability at higher doses than previously studied and an expected concentration increase in blood and cerebrospinal fluid. Beyond Alzheimer's disease, AlzeCure has indicated potential indications including Parkinson's disease and depression, with preclinical anti-inflammatory data presented at the AD/PD 2025 conference and mechanistic characterization data presented at AD/PD 2026 showing dose-dependent Trk receptor activation and antidepressant effects.
No approved small-molecule Trk-PAM exists for any neurological indication, placing ACD856 in a mechanistically unoccupied space. Competing approaches to the same BDNF/TrkB biology include gene therapy programs and BDNF mimetics, both largely preclinical and of different modalities.